Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Leuprorelin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Leuprorelin. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2022-002471-11 Sponsor Protocol Number: Leuprorelin-4002 Start Date*: 2022-08-08
    Sponsor Name:Takeda (China) International Trading Co., Ltd.
    Full Title: An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-015881-71 Sponsor Protocol Number: AMW/001/C Start Date*: 2010-02-12
    Sponsor Name:AMW GmbH
    Full Title: An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of two new GnRH implants (AMW Goserelin 3.6 mg...
    Medical condition: prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006975-41 Sponsor Protocol Number: URONCOR06-24 Start Date*: 2022-07-27
    Sponsor Name:GICOR
    Full Title: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomise...
    Medical condition: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006014-14 Sponsor Protocol Number: AMW/003/C Start Date*: 2012-04-27
    Sponsor Name:AMW GmbH
    Full Title: An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Leuprorelin 10.72 mg implant) appl...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001687-37 Sponsor Protocol Number: LEX/001/C Start Date*: 2008-07-08
    Sponsor Name:Novosis AG
    Full Title: An open label, parallel group phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 10.72 mg implant versus the reference product...
    Medical condition: Male patients with carcinoma of the prostate aged 18 years and more and suitable for hormonal manipulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000926-38 Sponsor Protocol Number: LEU/001/C Start Date*: 2008-05-08
    Sponsor Name:Novosis AG
    Full Title: An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 3.57 mg implant versus the ref...
    Medical condition: Patients who have advanced carcinoma of the prostate suitable for hormonal manipulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006474-28 Sponsor Protocol Number: NBI-56418-0703 Start Date*: 2008-05-14
    Sponsor Name:Neurocrine Biosciences, INC
    Full Title: A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects with Endometriosis
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014778 Endometriosis LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001750-25 Sponsor Protocol Number: B9R-FP-GDGI Start Date*: 2007-03-22
    Sponsor Name:LILLY FRANCE
    Full Title: Efficacy and Safety of Somatropin in Combination with Leuprorelin Compared to Somatropin Alone and to an Untreated Control Group in Pubertal Children with Idiopathic Short Stature
    Medical condition: Children with Idiopathic Short Stature (ISS) at puberty onset.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040600 Short stature LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004516-22 Sponsor Protocol Number: 04-4025 Start Date*: 2005-02-01
    Sponsor Name:Uppsala University
    Full Title: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022037-29 Sponsor Protocol Number: AFU-GETUG 20/0310 Start Date*: 2011-01-31
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of r...
    Medical condition: PROSTATIC ADENOCARCINOMA WITH HIGH RISK OF RECURRENCE.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Gender: Male
    Trial protocol: FR (Trial now transitioned) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004120-39 Sponsor Protocol Number: 1.0 Start Date*: 2017-03-13
    Sponsor Name:Region Skåne
    Full Title: An experimental pilot study on immune and inflammatory biomarkers in patients with advanced prostatecancer treated with degarelix vs. GnRH agonist and with cardiovascular disease
    Medical condition: Patients with advanced prostate cancer and pre-existing cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020825-42 Sponsor Protocol Number: RTOG0815 Start Date*: 2010-11-08
    Sponsor Name:Radiation Therapy Oncology Group
    Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
    Medical condition: intermediate risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005949-16 Sponsor Protocol Number: 202000894 Start Date*: 2021-10-25
    Sponsor Name:University Medical Center Groningen
    Full Title: A GnRH Agonist IN pre-menopausal women STudy to treat severe Polycystic Liver Disease
    Medical condition: Severe polycystic liver disease in female patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10048834 Polycystic liver disease PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036045 Polycystic kidney LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    23.0 10010331 - Congenital, familial and genetic disorders 10083939 Autosomal dominant polycystic liver disease LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000478-42 Sponsor Protocol Number: 008285QM Start Date*: 2013-02-18
    Sponsor Name:Queen Mary, University of London
    Full Title: NEPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer
    Medical condition: High or Intermediate Risk, Untreated, Clinically Localised Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008722-73 Sponsor Protocol Number: PPP/2008 Start Date*: 2009-04-20
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: ROLE OF PAROXETINE AS ADD-ON THERAPY TO GNRH AGONIST IN THE TREATMENT OF ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN
    Medical condition: Endometriosis-associated pelvic pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014778 Endometriosis LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004495-36 Sponsor Protocol Number: M90-516 Start Date*: 2014-11-28
    Sponsor Name:Abbvie previously known as Abbott
    Full Title: Study of Lupron Depot in the Treatment of Central Precocious Puberty
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001720-21 Sponsor Protocol Number: TAK-013/EC301 Start Date*: 2004-12-24
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-002791-14 Sponsor Protocol Number: 1707-CL-0011 Start Date*: 2013-02-14
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 ...
    Medical condition: endometriosis associated pelvic pain
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004872 10014788 Endometriosis related pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000160-15 Sponsor Protocol Number: MVT-601-3201 Start Date*: 2017-07-25
    Sponsor Name:Myovant Sciences GmbH
    Full Title: HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
    Medical condition: Androgen-sensitive advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) SK (Completed) DK (Completed) FI (Completed) ES (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005090-53 Sponsor Protocol Number: BAY98-7196/15832 Start Date*: 2014-09-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10014788 Endometriosis related pain LLT
    18.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed) DK (Completed) AT (Completed) BE (Completed) NL (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 00:33:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA